Last reviewed · How we verify
IGT-303
At a glance
| Generic name | IGT-303 |
|---|---|
| Sponsor | Ingenia Therapeutics INC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGT-303 CI brief — competitive landscape report
- IGT-303 updates RSS · CI watch RSS
- Ingenia Therapeutics INC portfolio CI